<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100956">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02074059</url>
  </required_header>
  <id_info>
    <org_study_id>03-CL-1201</org_study_id>
    <secondary_id>1R44HL107000-01</secondary_id>
    <nct_id>NCT02074059</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates</brief_title>
  <official_title>A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Discovery Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Discovery Laboratories, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of a single
      exposure of aerosolized surfactant, specifically lucinactant for inhalation, administered in
      escalating inhaled doses to preterm neonates 29 to 32 weeks gestational age who are
      receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress
      syndrome (RDS), compared to neonates receiving nCPAP alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and Tolerability of Lucinactant for Inhalation</measure>
    <time_frame>Day 7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessed during dosing by recording adverse reactions, oxygen saturation levels, and serum electrolytes; and following dosing by recording complications of prematurity and signs of worsening respiratory distress as evidenced by need for increased respiratory support and supplemental oxygen.&quot;</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Aerolized lucinactant low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose of lucinactant for inhalation with nCPAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Middle dose of lucinactant for inhalation with nCPAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of lucinactant for inhalation with nCPAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nCPAP alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nCPAP therapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lucinactant for Inhalation</intervention_name>
    <description>Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)</description>
    <arm_group_label>Aerolized lucinactant low dose</arm_group_label>
    <arm_group_label>Aerosolized lucinactant middle dose</arm_group_label>
    <arm_group_label>Aerosolized lucinactant high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nCPAP alone</intervention_name>
    <description>nCPAP therapy</description>
    <arm_group_label>nCPAP alone</arm_group_label>
    <other_name>nasal continuous positive airway pressure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent from a legally authorized representative

          -  Gestational age 29 to 32 completed weeks (32 weeks 6 days) post menstrual age (PMA)

          -  Successful implementation of controlled nCPAP within 60 minutes after birth

          -  Spontaneous breathing

          -  Chest radiograph consistent with RDS

          -  Need for moderate levels of supplemental oxygen and nCPAP to maintain oxygen
             saturation of 88%  to 95% for at least 60 minutes within the first 21 hours after
             birth

        Exclusion Criteria:

          -  Heart rate that cannot be stabilized above 100 beats/minute within 5 minutes of birth

          -  Recurrent episodes of apnea occurring after the initial newborn resuscitation period
             (ie, 10 minutes after birth) requiring intermittent positive pressure breaths using
             inflating pressures above the set CPAP pressure administered manually or mechanically
             through any patient interface

          -  A 5 minute Apgar score &lt; 5

          -  Major congenital malformation(s) and cranial/facial abnormalities that preclude
             nCPAP, diagnosed antenatally or immediately after birth

          -  Other diseases or conditions potentially interfering with cardiopulmonary function
             (eg, hydrops fetalis or congenital infection such as toxoplasmosis, rubella,
             cytomegalovirus, herpes simplex [TORCH])

          -  Known or suspected chromosomal abnormality or syndrome

          -  Prolong rupture of membranes (PROM) &gt; 2 weeks

          -  Evidence of hemodynamic instability requiring vasopressors or steroids for
             hemodynamic support

          -  Need for endotracheal intubation and mechanical ventilation

          -  Has been administered: another investigational agent or exposure to a medical device,
             any other surfactant agent, steroid treatment after birth
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Segal, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Discovery Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women and Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Arnell, RNC-NIC</last_name>
      <phone>858-939-4966</phone>
      <email>Kathy.Arnell@sharp.com</email>
    </contact>
    <investigator>
      <last_name>Anup Katheria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Maimi</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle McKay, MS</last_name>
      <phone>305-585-6527</phone>
      <email>IMcKay@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Cristina Naverrete, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children, University of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Smiley, CCRC</last_name>
      <phone>317-278-7364</phone>
      <email>lcsmiley@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Shawn Ahlfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Migaki</last_name>
      <phone>503-476-6606</phone>
      <email>Evelyn.Migaki@providence.org</email>
    </contact>
    <investigator>
      <last_name>Joseph W Kaempf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
